Kaori Ohmori-Matsuda

St. Michael's Hospital, Toronto, Ontario, Canada

Are you Kaori Ohmori-Matsuda?

Claim your profile

Publications (4)22.44 Total impact

  • M. Sato · K. Ohmori-Matsuda · T. Kondo · M. Chida · H. Date · M. Okumura · T. Oto · T. Shiraishi · T. Nagayasu
    [Show abstract] [Hide abstract]
    ABSTRACT: Cadaveric lung transplantation (LTx) in Japan has multiple limitations including 1) extreme donor shortage (only 44 cadaveric brain-death donors with 37 cadaveric LTx cases across Japan in 2011); 2) limited recipient age below 55 for bilateral and 60 for single LTx; 3) priority of LTx determined solely by waiting time on the list. Thus, living LTx could be the only life-saving option for those who cannot wait for cadaveric LTx. We examined the survival benefit of LTx (either cadaveric or living) among those who were listed for cadaveric LTx in Japan.Methods and MaterialsThe relative risks of death on the waiting list and death after LTx were evaluated using multivariate Cox models. Reception of LTx was treated as censored on the list. Since the initiation of the current Japanese listing system in 1998, patients who were listed by July 31, 2012 were included in the study.Results617 patients were listed and 174 received LTx (139 cadaveric, 35 living). Average waiting time for cadaveric LTx on the list was 966±676 (10-4507) days. In multivariate Cox regression models, idiopathic pulmonary fibrosis (IPF) showed the most significant risk of death on waiting list (n=115; hazard ratio (HR), 3.53; confidence interval (CI), 2.34-5.31; reference, PAH), while the risk of death after LTx (n=23, including cadaveric (n=15) and living (n=8)) was moderate (HR, 0.85; CI, 0.36-2.01; ref, PAH). Treating the conditions of being on cadacveric-LTx list and being post-LTx as time-dependent covariates, the estimated survival benefit of LTx was most significant in IPF (HR, 0.26; CI, 0.097-0.746). This trend persisted in subanalyses of living and cadaveric LTx.ConclusionsIPF showed the most significant survival benefit by LTx. This is explained by their poor prognosis without LTx and reasonable outcome after LTx. Adult-to-adult living LTx, which appears suitable for relatively old IPF patients with small thorax, remains the only life-saving option for many IPF patients who cannot wait for cadaveric LTx.
    The Journal of Heart and Lung Transplantation 04/2013; 32(4):S172. DOI:10.1016/j.healun.2013.01.410 · 5.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: The timing of disease onset may affect the prognosis in chronic lung allograft dysfunction (CLAD). The relationship between the timing of disease onset and the prognosis of CLAD and its sub-types, bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS), was examined. METHODS: Clinical records and pulmonary function data of 597 patients who underwent bilateral lung transplantation from 1996 to 2010 and survived for >3 months were examined. RESULTS: Among 155 patients with a final diagnosis of BOS, patient survival after disease onset was significantly different according to disease-onset timing (BOS onset/post-BOS median survival: overall/1,438 days; <1 year/511 days; 1-2 years/1,199 days; 2-3 years/1,403 days; >3 years/did not reach median survival; p < 0.0001). The prognosis of RAS was generally poorer than that of BOS (overall post-RAS median survival, 377 days). Treating non-CLAD, CLAD, BOS, and RAS as time-dependent covariates, recipient sex-adjusted and age-adjusted Cox regression analysis demonstrated an overall mortality risk of BOS (reference: no CLAD) of 6.7 (95% confidence interval, 4.6-9.9). However, when patients survived 3 years without CLAD, the mortality risk of subsequent BOS was only 1.9 (95% confidence interval, 0.8-4.4) compared with no CLAD. The number of RAS patients was too small to obtain sufficient power to estimate time-dependent mortality risk. CONCLUSION: Late-onset BOS showed a better prognosis than early-onset BOS. Studies that do not distinguish BOS from RAS may overestimate the mortality risk of BOS. Multicenter studies will be required to further elucidate risk factors toward the development of better management strategies for CLAD.
    The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 02/2013; 32(5). DOI:10.1016/j.healun.2013.01.1054 · 5.61 Impact Factor
  • M. Sato · K. Ohmori-Matsuda · L.G. Singer · S. Keshavjee
    The Journal of Heart and Lung Transplantation 04/2012; 31(4):S123. DOI:10.1016/j.healun.2012.01.355 · 5.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Diffuse alveolar damage (DAD) is a non-specific pathologic diagnosis frequently encountered after lung transplantation. We examined the relationship between DAD and different forms of chronic lung allograft dysfunction (CLAD). We reviewed the results of 4,085 transbronchial biopsies obtained from 720 lung transplant recipients. DAD detected in biopsies within 3 months and newly detected DAD after 3 months were defined as early DAD and late new-onset DAD, respectively. Among patients with CLAD (FEV(1) <80% baseline), restrictive allograft syndrome (RAS) was defined by a decline in total lung capacity to <90% baseline and bronchiolitis obliterans syndrome (BOS) as CLAD without restrictive allograft syndrome (RAS). Kaplan-Meier analyses and multivariate proportional hazard models were used. DAD was observed in 320 of 720 (44.4%) patients at least once; early and late new-onset DAD were observed in 264 of 707 (37.3%) and 87 of 655 (13.3%) patients, respectively. Early DAD was associated with significantly higher 90-day mortality (20 of 264 [7.6%] vs 11 of 443 [2.5%]; p = 0.001). Moreover, among 502 bilateral lung transplant recipients who had sufficient pulmonary function tests to distinguish BOS and RAS, early DAD was associated with earlier BOS onset (hazard ratio [HR] 1.24; confidence interval [CI] 1.04 to 1.47; p = 0.017; median time of BOS onset: 2,902 vs 4,005 days). Conversely, treated as a time-varying covariate, late new-onset DAD was a significant risk factor for RAS in a Cox model (HR 36.8; CI 18.3 to 74.1; p < 0.0001). Early DAD is associated with early mortality and BOS, and late new-onset DAD increases the risk of RAS.
    The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 02/2012; 31(4):354-63. DOI:10.1016/j.healun.2011.12.015 · 5.61 Impact Factor